Roche’s Genentech unit called in an option to license a second immuno-oncology target from its collaboration with British biotech Bicycle Therapeutics. Bicycle is built on technology that it originally used to attach toxins to innate immune activators, resulting in drugs designed to deliver payloads to cancer cells and trigger immune attacks localized within tumors. Source: Fierce Biotech 12/7/2022